MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Home・Akcijų sąrašas・MiNK Therapeutics

Search

MiNK Therapeutics

Uždarymo kaina

11.96 -2.05

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.55

Max

12.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.4M -2.9M
Pelnas, tenkantis vienai akcijai	-0.65
Darbuotojai	23
EBITDA	1.3M -2.8M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+196.11% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-6.2M 56M
Ankstesnė atidarymo kaina	14.01
Ankstesnė uždarymo kaina	11.96

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

7.81 / 8.1 Palaikymas ir pasipriešinimas

MiNK Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-22 21:55; UTC

Uždarbis

Capital One Financial Posts Higher 4Q Profit As Lending Increases

2026-01-22 23:52; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

2026-01-22 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

2026-01-22 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Profit-Taking -- Market Talk

2026-01-22 23:40; UTC

Rinkos pokalbiai

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

2026-01-22 23:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-22 23:30; UTC

Rinkos pokalbiai

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

2026-01-22 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

2026-01-22 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

2026-01-22 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-22 21:44; UTC

Uždarbis

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

2026-01-22 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

2026-01-22 21:31; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

2026-01-22 21:31; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

2026-01-22 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

2026-01-22 21:30; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

2026-01-22 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Capital One To Acquire Brex >COF

2026-01-22 21:13; UTC

Uždarbis

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

2026-01-22 21:10; UTC

Uždarbis

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

2026-01-22 21:06; UTC

Uždarbis

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Rev $15.58B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q EPS $3.26 >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net Interest Margin 8.26% >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net $2.13B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Adj EPS $3.86 >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net Charge-Offs $3.8B >COF

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q EPS $2.21 >ISRG

Akcijų palyginimas

Kainos pokytis

MiNK Therapeutics Prognozė

Kainos tikslas

By TipRanks

196.11% į viršų

12 mėnesių prognozė

Vidutinis 35 USD 196.11%

Aukščiausias 35 USD

Žemiausias 35 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MiNK Therapeutics kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Remiantis 1 analitikų, pateikusių MiNK Therapeutics akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

7.81 / 8.1Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Kitos sektoriaus akcijos

MDT

Medtronic PLC

101.45

A

Agilent Technologies Inc

138.61

VEEV

Veeva Systems Inc

225

HQY

HealthEquity Inc

86.43

NEOG

Neogen Corp

9.92

Live chat